Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Oteseconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 151,749Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mycovia Publishes 2-Year VIVJOA Results in RVVC Phase 3 Study
    Mycovia Publishes 2-Year VIVJOA Results in RVVC Phase 3 Study

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-publication-of-2-year-vivjoa-efficacy-results-from-an-extension-of-the-violet-phase-3-studies-in-women-with-recurrent-vulvovaginal-candidiasis-rvvc-in-the-journal-of-womens-health-302617754.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa

    02 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-recognition-for-the-inclusion-of-vivjoa-oteseconazole-capsules-in-the-chinese-national-reimbursement-drug-list-302417640.html

    PR NEWSWIRE
    02 Apr 2025
    Share Share
    Mycovia Presents VIVJOA® Safety Studies At IDSOG 2024
    Mycovia Presents VIVJOA® Safety Studies At IDSOG 2024

    01 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-announces-presentation-of-results-from-three-safety-studies-evaluating-vivjoa-oteseconazole-in-subjects-with-renal-or-hepatic-impairment-and-the-impact-on-qt-prolongation-at-the-2024-idsog-annual-meetin-302211538.html

    PR NEWSWIRE
    01 Aug 2024
    Share Share
    Mycovia Announces AllianceRx Walgreens Pharmacy as Distributor of VIVJOA®
    Mycovia Announces AllianceRx Walgreens Pharmacy as Distributor of VIVJOA®

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-alliancerx-walgreens-pharmacy-and-walgreens-community-based-specialty-pharmacies-as-exclusive-distributor-of-vivjoa-302098255.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share
    Mycovia Announces Partner Jiangsu Hengrui's Commercial Launch of VIVJOA
    Mycovia Announces Partner Jiangsu Hengrui's Commercial Launch of VIVJOA

    07 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-commercial-launch-of-vivjoa-oteseconazole-capsules-for-the-treatment-of-severe-vulvovaginal-candidiasis-vvc-in-china-302046980.html

    PR NEWSWIRE
    07 Feb 2024
    Share Share
    Mycovia Announces Partner Jiangsu Hengrui's Approval of Oteseconazole Capsules
    Mycovia Announces Partner Jiangsu Hengrui's Approval of Oteseconazole Capsules

    21 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-approval-of-oteseconazole-capsules-for-the-treatment-of-severe-vulvovaginal-candidiasis-vvc-in-china-301904626.html

    PR NEWSWIRE
    21 Aug 2023
    Share Share